α-synuclein imaging: A critical need for parkinson's disease research

Journal of Parkinson's Disease

Volumn 3, Issue 4, 2013, Pages 565-567

  Eberling, Jamie L ^a   Dave, Kuldip D ^a   Frasier, Mark A ^a  

^a THE MICHAEL J FOX FOUNDATION FOR PARKINSON'S RESEARCH   (United States)

Author keywords

Biomarker; Positron emission tomography; Radiopharmaceutical; Tau; Synuclein; amyloid

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AZD 4694 F 18; CARBON 11; FLORBETABEN; FLORBETAPIR F 18; FLUORINE 18; FLUTEMETAMOL F 18; MK 3328 F 18; PITTSBURGH COMPOUND B; TAU PROTEIN; TRACER; UNCLASSIFIED DRUG;

ARTICLE; DRUG DEVELOPMENT; MEDICAL RESEARCH; NEUROIMAGING; PARKINSON DISEASE; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

BIOMARKER; POSITRON EMISSION TOMOGRAPHY; RADIOPHARMACEUTICAL; TAU; Α-SYNUCLEIN; Β-AMYLOID;

ALPHA-SYNUCLEIN; BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; BRAIN; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84894244854     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-130247     Document Type: Article

References (17)

1. Cookson MR (2009) Alpha-Synuclein and neuronal cell death. Mol Neurodegene, 4, 9.
2. Mollenhauer B, & Zhang J (2012) Biochemical premotor biomarkers for Parkinson's disease. Mov Disord 27, 644-650.
3. Zeng F, & Goodman MM (2013) Fluorine-18 radiolabeled heterocycles as PET tracers for imaging beta-amyloid plaques in Alzheimer's disease. Curr Top Med Chem, 13, 909-919.
4. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, & Grundman M (2010) 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9, 363-372.
5. Blennow K, Hampel H, & Zetterberg H (2013) Biomarkers in Amyloid-beta Immunotherapy Trials in Alzheimer's Disease. Neuropsychopharmacology Reviews, 1-13.
6. Vekrellis K, & Stefanis L (2012) Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies. Expert Opin Ther Targets, 16, 421-432.
7. Schneeberger A, Mandler M, Mattner F,&SchmidtW(2012) Vaccination for Parkinson's disease. Parkinsonism Relat Disord, 18(Suppl 1), S11-S13.
8. Bellucci A, Navarria L, Zaltieri M, Missale C, & Spano P (2012) Alpha-Synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease. Brain Res, 1432, 95-113.
9. Fleming SM, Mulligan CK, Richter F, Mortazavi F, Lemesre V, Frias C, Zhu C, Stewart A, Gozes I, Morimoto B, & Chesselet MF (2011) A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. Mol Cell Neurosci 46, 597-606.
10. Klunk WE,Wang Y, Huang GF, Debnath, ML, Holt DP, Shao L, Hamilton RL, IkonomovicMD,DeKosky ST,&MathisCA (2003) The binding of 2-(4'- methylaminophenyl) benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci, 23, 2086-2092.
11. Villemagne VL, Furumoto S, Fodero-Tavoletti M, Harada R, Mulligan RS, Kudo Y, Masters CL, Yanai K, Rowe CC, & Okamura N (2012) The challenges of tau imaging. Future Neurol, 7, 409-421.
12. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ,&LeeVM(2012) Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science, 338, 949-953.
13. Bagchi DP, Yu L, Perlmutter JS, Xu J, Mach RH, Tu Z, & Kotzbauer PT (2013) Binding of the radioligand SIL23 to alpha-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent. PLoS ONE, 8, e55031.
14. Lyon RA, Titeler M, Frost JJ, Whitehouse PJ,Wong DF,Wagner HN, Jr., Dannals RF, Links JM, & Kuhar MJ (1986) 3H-3-N-methylspiperone labels D2 dopamine receptors in basal ganglia and S2 serotonin receptors in cerebral cortex. J Neurosci, 6, 2941-2949.
15. Heiss WD, & Herholz K (2006) Brain receptor imaging. J Nucl Med, 47, 302-312.
16. Alzheimer Research Forum,TauTracers Shine at Boston Conference: http://www.alzforum.org/new/detail.asp?id=3561, Last update July 31, 2013, Accessed on August 20, 2013.
17. Magen I, & Chesselet MF (2010) Genetic mouse models of Parkinson's disease The state of the art. Prog Brain Res, 184, 53-87.